Covaxin induced robust immune response in Phase 1 trials: Bharat Biotech

India’s first indigenous vaccine Covaxin was successful in inducing a robust immune response without any serious adverse events during the Phase 1 trials that were conducted on 375 volunteers. The company said a majority of the adverse events observed during the study were mild and successfully resolved.